Global /Australia /Healthcare /Biotechnology /NSB

NeuroScientific Biopharmaceuticals Ltd.

NSB

• ASX: NSB • Delayed

0.1050AUD -4.6%

0.0740 USD

As of 15 June 2026, NeuroScientific Biopharmaceuticals Ltd. has a market cap of $25.71M USD, ranking #35334 globally and #969 in Australia. It ranks #3188 in the Healthcare sector, and #616 in the Biotechnology industry.

Global Rank

35334

Country Rank

969

Sector Rank

3188

Industry Rank

616

Key Stats

Market Cap

$25.71MUSD

36.58M AUD

Enterprise Value

$21.29MUSD

30.23M AUD

Revenue (TTM)

$223.46KUSD

317.91K AUD

EBITDA (TTM)

-$1.9MUSD

-2.7M AUD

Net Income (TTM)

-$2.23MUSD

-3.18M AUD

PS Ratio

115.1

PB Ratio

2.2

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Biotechnology

CEO

Nathan Smith open_in_new

Founded

2002

Website

neuroscientific.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.6%	-4.3%	55%	-19%	-4.3%	-37%	112%	57%	-63%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	NSB Neuroscientific Biopharmaceuticals Ltd Ordinary Shares ISIN: AU0000012973 Shares Out.: Shares Outstanding: 389.719M¹ TV: TradingView: ASX: NSB SA: Stock Analysis: ASX: NSB YF: Yahoo Finance: NSB.AX GF: Google Finance: ASX: NSB BA: Barron's: NSB MS: Morningstar: XASX: NSB	0.1050 AUD	TV: TradingView: ASX: NSB SA: Stock Analysis: ASX: NSB YF: Yahoo Finance: NSB.AX GF: Google Finance: ASX: NSB BA: Barron's: NSB MS: Morningstar: XASX: NSB

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About NeuroScientific Biopharmaceuticals Ltd.

NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.

Similar Companies

Industry: Biotechnology (Australia)

Name	Market Cap (USD) diff.	PE	Country
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 165K%	29.3	Australia
Telix Pharmaceuticals Ltd. ASX: TLX	$3.58B 5.09B AUD 14K%	-	Australia
Mesoblast Ltd. ASX: MSB	$2.02B 2.88B AUD 8K%	-	Australia
PolyNovo Ltd. ASX: PNV	$490.46M 697.75M AUD 2K%	71.8	Australia
Kazia Therapeutics Ltd. NASDAQ: KZIA	$141.64M 451%	-	Australia
Immutep Ltd. ASX: IMM	$65.26M 92.84M AUD 154%	-	Australia

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 709K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 622K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 186K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 174K%	35.5	South Korea
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 164K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 109K%	43.8	South Korea

chevron_leftBack